Matinas Biopharma Holdings (MTNB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Matinas Biopharma Holdings (MTNB) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.42 of bullish evidence against -0.54 bearish.

Matinas Biopharma Holdings last closed at $2.83, +2.17% on the session.

Against the IVW growth benchmark the position is +1.37% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

19 graded predictions for MTNB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Matinas Biopharma Holdings in the 6th percentile on return on equity, where 100 is best.

Matinas Biopharma Holdings is classified under Health Care / Biotechnology, with a market capitalisation of $2.77M.

StockMap tracks Matinas Biopharma Holdings as the 376th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Matinas Biopharma Holdings ranks 350th of 381 in the group, against a group median of -0.08.